Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.37 |
| ▸ | PRKCI | P41743 | 7/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | MC5R | P33032 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PRKX | P51817 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514249 | 0.82 | ROCK2 (0.37) | CITROCK2PRKCIROCK1PPARG | |
| SCHEMBL27509941 | 0.81 | SLC7A5 (0.47) | SLC7A5MC4RMC5RMC3R | |
| SCHEMBL5961039 | 0.81 | SLC7A5 (0.47) | SLC7A5MC4RMC5RMC3R | |
| SCHEMBL5961037 | 0.81 | SLC7A5 (0.47) | SLC7A5MC4RMC5RMC3R | |
| SCHEMBL4527459 | 0.81 | GPR142 (0.43) | ROCK1 | |
| SCHEMBL4514376 | 0.81 | GPR142 (0.43) | ROCK1 | |
| SCHEMBL4512482 | 0.80 | CTSS (0.38) | ROCK1PRKACA | |
| SCHEMBL4524956 | 0.80 | ROCK1 (0.50) | ROCK2ROCK1SLC7A5CYP3A4PRKACA | |
| SCHEMBL4526794 | 0.78 | TPH1 (0.39) | — | |
| SCHEMBL4528517 | 0.78 | SLC7A5 (0.43) | CITSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | CIT 7/4885ROCK2 2/4885PRKCI 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.